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ARTICLE OPEN
Psychiatric-disorder-related behavioral phenotypes and
cortical hyperactivity in a mouse model of 3q29 deletion
syndrome
Masayuki Baba1, Kazumasa Yokoyama2, Kaoru Seiriki1,3, Yuichiro Naka1, Kensuke Matsumura1,3,4, Momoka Kondo1, Kana Yamamoto1,
Misuzu Hayashida1, Atsushi Kasai 1, Yukio Ago 1,5, Kazuki Nagayasu1, Atsuko Hayata-Takano1,6, Akinori Takahashi7,
Shun Yamaguchi8,9, Daisuke Mori 10,11, Norio Ozaki 10, Tadashi Yamamoto7,12, Kazuhiro Takuma 6,13, Ryota Hashimoto14,15,
Hitoshi Hashimoto 1,6,16,17 and Takanobu Nakazawa 1,13
3q29 microdeletion, a rare recurrent copy number variant (CNV), greatly confers an increased risk of psychiatric disorders, such as
schizophrenia and autism spectrum disorder (ASD), as well as intellectual disability. However, disease-relevant cellular phenotypes
of 3q29 deletion syndrome remain to be identified. To reveal the molecular and cellular etiology of 3q29 deletion syndrome, we
generated a mouse model of human 3q29 deletion syndrome by chromosome engineering, which achieved construct validity.
3q29 deletion (Df/+) mice showed reduced body weight and brain volume and, more importantly, impaired social interaction and
prepulse inhibition. Importantly, the schizophrenia-related impaired prepulse inhibition was reversed by administration of
antipsychotics. These findings are reminiscent of the growth defects and neuropsychiatric behavioral phenotypes in patients with
3q29 deletion syndrome and exemplify that the mouse model achieves some part of face validity and predictive validity. Unbiased
whole-brain imaging revealed that neuronal hyperactivation after a behavioral task was strikingly exaggerated in a restricted region
of the cortex of Df/+ mice. We further elucidated the cellular phenotypes of neuronal hyperactivation and the reduction of
parvalbumin expression in the cortex of Df/+ mice. Thus, the 3q29 mouse model provides invaluable insight into the disease-
causative molecular and cellular pathology of psychiatric disorders.
Neuropsychopharmacology (2019) 44:2125–2135; https://doi.org/10.1038/s41386-019-0441-5
INTRODUCTION
Accumulating evidence suggests that psychiatric disorders are
strongly associated with rare variants with high penetrance, in
addition to the potential cumulative effect of a large number of
common genetic variants with small individual effects [1–3]. The
most well-characterized forms of rare but recurrent variations are
copy number variants (CNVs), which represent large genomic
duplications or deletions. Rare but recurrent CNVs have been
widely considered to contribute to genetic vulnerability to
psychiatric disorders, including schizophrenia and autism spec-
trum disorders (ASDs) [4–7]. A recent genome-wide study has
shown that eight loci, including 1q21.1 (deletion and duplication),
2p16.3 (NRXN1) (deletion), 3q29 (deletion), 7q11.23 (duplication),
15q13.3 (deletion), distal 16p11.2 (deletion), proximal 16p11.2
(duplication), and 22q11.2 (deletion), are associated with a high
risk for psychiatric disorders (odds ratio, 3.8-infinite) [8]. Impor-
tantly, approximately 2.5% of patients with schizophrenia carry at
least one of these CNVs [9].
The 3q29 microdeletion is mostly de novo and the incidence for
the microdeletion is 1 in 30,000–40,000 birth [5, 10–13]. The 3q29
microdeletion is typically approximately 1.6 Mb in size and
contains approximately 22 genes. The 3q29 microdeletion is
associated with ASD, bipolar disorder, intellectual disability, and
schizophrenia [13–17]. Particularly, among the schizophrenia-
associated CNVs, the 3q29 microdeletion is likely to confer the
greatest risk for schizophrenia (40 to infinite increase in risk) [13].
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In addition to these diseases, the 3q29 microdeletion is also
associated with speech delay, anxiety, and microcephaly [5]. To
date, while a mouse model of 3q29 deletion syndrome has been
reported very recently [18], there are few studies on the effect of
the 3q29 microdeletion on neural function. Accordingly, disease-
relevant cellular phenotypes of 3q29 deletion syndrome are
almost completely unclear.
Psychiatric disorders, such as schizophrenia and ASD, share, in
part, genetic causes, pathophysiology, and clinical symptoms.
Central nervous development and neuronal circuit functions are
commonly impaired in patients with these disorders. In particular,
multiple lines of evidence suggest that an altered cellular balance
of excitation and inhibition (E/I balance) within neural circuitry is a
shared pathophysiological mechanism for schizophrenia and ASD
[19]. Consistent with this, studies of postmortem brains show that
GABAergic interneuron density and distribution are altered in
patients with schizophrenia [20–24]. Importantly, the expression of
GABA-related molecules, including the GABA-synthesizing
enzymes GAD67, GABA membrane transporter GAT1, GABA
receptor subunits, parvalbumin (PV), somatostatin, cholecystoki-
nin, neuropeptide Y, calretinin, and calbindin, is altered in patients
with schizophrenia [22, 25, 26]. In addition to schizophrenia,
GABAergic neurotransmission is suggested to be impaired in
patients with ASD [27]. Because GABAergic interneurons regulate
a number of brain functions that govern cognitive and emotional
behaviors [22, 28, 29], impaired brain functions in patients with
psychiatric disorders is in part caused by abnormalities in the
GABAergic system.
Given that rare recurrent pathological CNVs of patients with
psychiatric disorders show extraordinarily high penetrance [8],
genetically engineered mice harboring these CNVs are important
models for investigation of relevant phenotypes associated with
psychiatric disorders. In this paper, to study the impact of the 3q29
microdeletion on neuronal functions in vivo, we generated
genetically engineered mice harboring a deletion of the
chromosomal region corresponding to the human 3q29 region
through Cre-mediated recombination. Del(16Bdh1-Tfrc)/+ mice
(heterozygous 3q29 deletion mice; hereafter Df/+ mice) showed
slightly reduced body weight as well as brain volume. Df/+ mice
also showed psychiatric disorder-related behavioral phenotypes in
the schizophrenia-related prepulse inhibition (PPI) test, ASD-
related reciprocal interaction test and self-grooming test, and
contextual fear conditioning test. Importantly, impaired PPI was
reversed by risperidone treatment. Using FAST (block-FAce Serial
microscopy Tomography), a high-speed serial-sectioning imaging
system that allows us to unbiasedly analyze whole-brain neural
activity [30, 31], we found that neuronal activity was abnormally
activated in a restricted region of the cortex of Df/+ mice. In the
cortex of Df/+ mice, we found that the expression levels of
immediate early genes were increased and that the number of PV-
positive neurons was decreased. Taken together, our current
findings suggest that heterozygous 3q29 deletion impairs the
GABAergic system, leading to increased cortical neuronal activity
and psychiatric disorder-related behavioral phenotypes. Df/+
mice can help better understand the disease-causative molecular
etiology of psychiatric disorders and develop new and better
treatments for psychiatric disorders.
MATERIALS AND METHODS
All procedures were performed in accordance with the standards
of humane care, and the treatment of the research animals was
approved by the Institutional Animal Care and Use Committee in
Takeda Pharmaceutical Company Limited, Osaka University and
Okinawa Institute of Science and Technology Graduate University.
All recombinant DNA experiments were reviewed and approved
by the Gene Modification Experiments Safety Committee of
Takeda Pharmaceutical Company Limited and Osaka University.
Generation of a mouse model of 3q29 syndrome
The common breakpoint regions in human 3q29 deletion
syndrome were analyzed with NCBI BLAST to find region-specific
low-copy repeats (LCRs), which may facilitate 3q29 microdeletion
[11]. Genomic coordinates of the LCRs in UCSC hg19 were
converted to mouse genomic coordinates in UCSC mm10 with
liftOver. The human 3q29 region between LCRs corresponds to
mouse chromosome 16: 31,336,396–32,632,800. We constructed
two targeting vectors and two pairs of CRISPR single guide RNAs
to insert loxPs into mouse chromosome 16: 31,415,600, just
proximal to Bdh1, and 32,632,500, just distal to Tfrc, with the
hygromycin resistance gene and the puromycin resistance gene,
respectively. These vectors, along with a Cas9 nickase plasmid,
were electroporated into embryonic stem (ES) cells derived from
C57BL/6J mice and selected successively with hygromycin and
puromycin. We utilized the Cas9 nickase (D10A) mutant to reduce
off-target mutagenesis [32, 33]. Selected clones were transiently
transfected with a Cre recombinase plasmid and tested for copy
number analysis of the Bdh1-Tfrc region by genome quantitative
PCR (qPCR) analysis, by which ES cells harboring two loxP sites in
cis resulted in a chromosome deletion and apparent reduction in
the genome copy number of the Bdh1-Tfrc region, whereas cells
harboring two loxP sites in trans resulted in a balanced duplication
and deletion and unaltered genome copy number. In this study, a
deleted ES clone was injected into tetraploid blastocysts of the ICR
strain, and chimeric mice were bred with C57BL/6J female mice to
generate Del(16Bdh1-Tfrc)/+ mice (heterozygous 3q29 deletion
mice; Df/+ mice). Transmission of a Bdh1-Tfrc deletion was
confirmed by genome qPCR.
RNA sequence
Total RNA isolated from 8-week-old mouse brains was sequenced
using an Illumina system (Macrogen Inc., Seoul, Korea). UCSC
mm10 was used as a reference genome to map complementary
DNA fragments obtained from RNA-sequencing. The fragments per
kilobase of transcript per million mapped reads value was used as
the expression profile. The significant results were selected on
conditions of |FC| >2 and independent t test raw P < 0.05. Based on
these criteria, seven genes were differentially expressed between
Df/+ mice and wild-type (WT) littermates (n= 3).
Behavioral analysis
All behavioral analyses were carried out on male C57BL/6J mice at
approximately 2 months of age. Three different mouse batches
were used for behavioral analyses. The first one was used for the
self-grooming test, social interaction test, and PPI test in this order.
The second one was used for the open-field test and contextual
fear conditioning test in this order. The last one was used for the
PPI test with risperidone. All behavioral analyses were performed
during the light period in a completely blinded manner.
PPI test
A startle chamber (SR-LAB, San Diego Instruments, CA, USA) was
used to assess the acoustic startle responses and PPI as
described previously [34]. Briefly, after a background noise of
65 dB was presented for 5 min, the following experimental
sessions were performed. Each mouse was exposed to four
consecutive blocks with a total of 100 trials within approxi-
mately 30 min. One block consisted of five different trial types,
including pulse-alone trials (40 ms broadband 120 dB burst),
three different prepulse-pulse trials (3, 6, and 9 dB prepulse
intensities above the 65 dB background noise and 120 dB startle
pulse) and no-stimulation trials. The startle response was
recorded for 100 ms. The percentage of PPI was calculated as
[(startle amplitude without prepulse) – (startle amplitude with
prepulse)]/(startle amplitude without prepulse) × 100. With this
standard method, impaired PPI is suggested to be relevant to
schizophrenia, but not to ASD [7].
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Reciprocal social interaction test
The reciprocal social interaction test was performed as described
previously [35–37]. Briefly, a male intruder mouse was placed in
the test cage after habituation of the test mouse to the same cage
for 60 min. Over the whole experimental period (20 min), the total
duration of time that the resident mouse spent sniffing, following,
allo-grooming, and push-crawling the intruder was measured.
Self-grooming test
After a 10-min period of habituation to a test cage, the cumulative
time that the test mouse spent grooming itself in the test cage
was manually measured for 10min.
Contextual fear conditioning test
Fear conditioning was conducted in a fear conditioning chamber
(30 × 24 × 21 cm3, Med Associates Inc., VT, USA). Each mouse was
placed in the chamber for 120 s, and then the mouse was given a
footshock (5 s/ 0.8 mA) (4 times with a 30-s intershock interval). On
the test day, the mouse was placed in the same chamber as used
in the conditioning. Then, the freezing response was measured for
6 min. Freezing was monitored by Med Associates Video Freeze
software.
Open-field test
Locomotor activity was measured as described previously [38].
Briefly, each mouse was placed in the center of the apparatus
(45 × 45 × 30 cm3). The total distance traveled and time spent in
the center zone (25 × 25 cm2) were recorded for 90 and 5min,
respectively, per mouse.
Real-time PCR
Total RNA isolated from cortices was reverse transcribed with
Superscript III (Life Technologies, CA, USA). Using SYBR Premix EX
Taq (Takara Bio Inc., Shiga, Japan), real-time PCR was performed
with a CFX96 real-time PCR detection system (Bio-Rad Labora-
tories, CA, USA) according to the manufacturer’s instructions. The
expression levels of each gene were normalized to those of Gapdh
and were determined according to the 2-ΔΔCt method. The primers
used were as follows: Egr2, 5′-CTACCCGGTGGAAGACCTC-3′ and 5′-
AATGTTGATCATGCCATCTCC-3′; Fos, 5′-GGCTCTCCTGTCAACACAC
A-3′ and 5′-GACCAGAGTGGGCTGCAC-3′; Cyr61, 5′-GCCAAGAAGAA
TAAGAGATGTGATTA-3′ and 5′-AGGGGGCTTGGAGTCCTT-3′; Nr4a1,
5′-GGGGGAGTGTGCTAGAAGG-3’ and 5′-TTGAATACAGGGCATCTC
CA-3′; Btg2, 5′-GTTTTCAGTAGGGCGCTCCAGGAC-3′ and 5′-TGGT
TGATACGGATACAGCGATAG-3′; Dusp1, 5′-CTGGAGAACCGCAGAAC
G-3′ and 5′-GATGCCCACCTCCATCAC-3′; Gapdh, 5′-GTGTTCCT
ACCCCCAATGTG-3′ and 5′-TACCAGGAAATGAGCTTGAC-3′.
Administration of risperidone
Risperidone (Sigma-Aldrich, MO, USA) dissolved in saline (0.9%
NaCl solution) containing <0.1% (v/v) acetic acid was intraper-
itoneally administered to adult male mice at a dosage of 1 mg/kg
30min before the PPI test.
FAST whole-brain imaging
Adult male Df/+ mice and WT littermates, both of which were
crossed with Arc-dVenus mice [39], were subjected to the
reciprocal social interaction test. Five hours after the test, which
is the peak time of dVenus expression driven by the Arc promoter,
the mice were perfused with 4% paraformaldehyde (PFA) in
phosphate-buffered saline (PBS) to fix the brain. Serial whole-brain
imaging was performed using FAST, which renders brain-wide
anatomical and functional analyses at the single-cell level,
including cell-type-specific activity mapping of disease model
brains with various reporter animals [30, 31]. Briefly, the mouse
brain was embedded in 4% agarose gel (Nacalai tesque, Kyoto,
Japan) dissolved in PBS and subjected to automated serial section
imaging. Whole-brain images were obtained at a resolution of
1.0 × 1.0 × 5 µm3 using FAST with a ×16 NA 0.8 objective lens
(Nikon instruments, Tokyo, Japan), a ×0.83 intermediate magnifi-
cation lens (Yokogawa Electronic, Tokyo, Japan), and an sCMOS
camera (Andor Technology, Belfast, UK) with a 2 × 2 binning
mode. Quantification of dVenus-positive neurons and semiauto-
matic anatomical parcellation of the brain were performed using
TRI/FCS-NUC64 software (Ratoc System Engineering, Tokyo,
Japan).
Histological analysis
Adult mouse brains were fixed with 4% PFA in PBS overnight at
4°C and were sectioned at a 50 μm thickness using a linear slicer
(Linear Slicer Pro7, Dosaka EM, Kyoto, Japan) for PV staining and
at a 20 μm thickness using a cryostat (Leica, Wetzlar, Germany,
CM1520) for SATB2 staining. For PV staining, the brain slices
were permeabilized with blocking solution containing 0.1%
Triton X-100 (Wako, Osaka, Japan) and 5% normal goat serum
(Thermo Fisher Scientific, Waltham, MA, USA) Tris-buffered saline
for 1 h at room temperature and then incubated with the
blocking solution combined with primary antibodies. For
SATB2 staining, the antigen was retrieved by microwave
treatment for 20 min in boiling 10 mM citric acid, pH 7.0,
followed by 20 min treatment in Histo VT one (Nacalai Tesque,
Kyoto, Japan) at 70 °C. Then, the brain slices were permeabilized
with blocking solution containing 0.25% Triton X-100 (Wako,
Osaka, Japan), 1% normal goat serum (Thermo Fisher Scientific),
and 1% bovine serum albumin (Sigma-Aldrich) in PBS for 1 h at
room temperature and then incubated with the blocking
solution combined with primary antibodies. The following day,
the slices were incubated with the blocking solution combined
with secondary antibody for 1 h at room temperature. Images of
the slices were acquired using an Olympus FluoView FV1000
confocal microscope (Olympus, Tokyo, Japan) and a BZ-9000
microscope (Keyence, Osaka, Japan). Then, the images were
analyzed with ImageJ software (NIH, Bethesda, MD, USA) and
Adobe Photoshop CS (Adobe Systems, San Jose, CA, USA). The
primary antibodies used were mouse anti-SATB2 (Abcam,
Cambridge, UK) and mouse anti-PV (Swant, Marly, Switzerland).
The secondary antibodies used were biotinylated goat anti-
mouse IgG antibody (Vector Laboratories, Burlingame, CA, USA)
and Texas Red streptavidin (Vector Laboratories).
Statistical analysis
The body weights of Df/+ mice and WT littermates were
statistically analyzed using Student’s t test and two-way analysis
of variance (ANOVA) with repeated measures followed by
Bonferroni post hoc tests. The behavioral data were statistically
analyzed using one-way ANOVA and two-way ANOVA followed by
Bonferroni post hoc tests. The quantified data from the
immunohistochemistry were statistically analyzed using Student’s
t test. The RNA sequence data were statistically analyzed by an
unpaired t test. The whole-brain imaging data were statistically
analyzed by Student’s t test. The Benjamin–Hochberg procedure
was used to correct P value for multiple comparisons. For details,
see the description in each figure legend. The significance level
was set at P < 0.05. Statistical analyses were conducted using Stat-
View (SAS Institute, Cary, NC, USA).
RESULTS
Generation of a mouse model of 3q29 deletion syndrome
Mouse chromosome 16 contains a syntenic region to human
chromosome 3q29 with the same gene order (Fig. 1a). To
generate a mouse model of 3q29 deletion syndrome, we
constructed two targeting vectors to insert loxP sites to the
regions in mouse chromosome 16 corresponding to common
breakpoints in human 3q29 deletion syndrome [11]: one was
proximal to Bdh1 and the other distal to Tfrc (Supplementary
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Fig. 1). ES cells derived from C57BL/6J mice were introduced with
the targeting vectors and chromosome engineered by expressing
Cre recombinase. Several clones were tested for copy number
analysis of the Bdh1-Tfrc region by genome qPCR analysis (data
not shown). The ES cells harboring the deletion were injected into
tetraploid blastocysts of the ICR strain, and chimeric mice were
bred with C57BL/6J female mice, resulting in the generation of Del
(16Bdh1-Tfrc)/+ mice (heterozygous 3q29 deletion mice; hereafter
Df/+ mice). To avoid any maternal effects of the deletion, we
mated male Df/+ mice with female WT C57BL/6J mice to obtain
Df/+ mice and their WT littermates for all experiments except the
whole-brain imaging.
Df/+ mice were born at the expected Mendelian ratios (birth
ratios from Df/+ and WT mice crosses: WT, 378/678 (55.75 %);
Df/+, 300/678 (44.25 %)). To validate the 3q29 deletion mouse
model, we analyzed the copy number of genes between the Bdh1
and Tfrc genes by genome qPCR analysis and found that each
gene copy number was decreased by approximately 50% in Df/+
mice, as expected (Supplementary Fig. 1b). Df/+ mice survived
into adulthood and appeared healthy but were slightly smaller
than WT littermates in both sexes (Fig. 1b and data not shown).
The significantly reduced body weight of Df/+ mice was evident
at embryonic day 18.5 (Fig. 1c). Importantly, Df/+ mice also
showed a significant reduction in brain weight (Fig. 1d), all of
which is reminiscent of the growth defects and small head size in
patients with 3q29 microdeletion syndrome [15]. We then
determined the mRNA expression levels of the genes between
the Bdh1 and Tfrc genes by quantitative reverse transcription PCR
Fig. 1 Characterization of Df/+ mice, a mouse model for the human 3q29 deletion. a The deleted region in human chromosome 3q29 (top)
and the syntenic region in mouse 16B2,3 (bottom). b Decreased body size in Df/+ mice (12 weeks old). Scale bar, 1 cm (left). Quantification of
body weight in WT and Df/+ mice (WT, n= 23; Df/+, n= 22) (right). **P < 0.01, repeated two-way analysis of variance (ANOVA). WT, wild-type
littermates. c Decreased body weight in Df/+ mice (embryonic day 18.5) (WT, n= 18; Df/+, n= 11). *P < 0.05, Student’s t test. d Reduced brain
weight in Df/+ mice (12 weeks old) (WT, n= 10; Df/+, n= 10). ***P < 0.001, Student’s t test. e Messenger RNA (mRNA) expression changes in
the cerebral cortex measured by RNA sequencing in 12-week-old Df/+ mice compared to WT mice (each n= 3). *Corrected P < 0.05, unpaired
t test with Benjamin–Hochberg false discovery rate correction. Data are presented as the mean ± s.e.m.
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(RT-PCR). The mRNA levels of these genes were decreased by
approximately 50% in Df/+ mice compared to those of WT
littermates (Fig. 1e). Taken together, our results show that Df/+
mice recapitulate a genomic disorder caused by a rare CNV.
Psychiatric disease-related behavioral phenotypes in heterozygous
3q29 deletion mice
Since 3q29 microdeletion syndrome is associated with ASD and
schizophrenia, we performed behavioral tests related to psychia-
tric disorders. The PPI test provides an operational measure of the
sensorimotor gating system, which is impaired in patients with
schizophrenia [40]. Before the tests, we measured the startle
amplitude of Df/+ mice and WT littermates and determined that
the startle response of Df/+ mice was significantly greater than
that of WT littermates (Fig. 2a). In Df/+mice, the percent of the PPI
of the startle reflex was significantly lower than that of WT
littermates (Fig. 2b), indicating impaired sensory-motor gating. We
next performed the reciprocal social interaction and self-grooming
tests that model the clinical features of ASD [41]. In the reciprocal
social interaction test, in which dyadic pairs of mice freely move
and mutually interact with each other in an open arena, Df/+mice
spent less time on social activities, such as sniffing, following, and
crawling over/under the partner’s body (Fig. 2c). We then assessed
repetitive self-grooming behavior and found that Df/+ mice
groomed much more than WT littermates (Fig. 2d). Furthermore,
Df/+ mice showed significantly weaker freezing responses in the
contextual fear conditioning test, suggesting impaired fear-related
learning (Fig. 2e). Additionally, we assessed the activity of Df/+
mice in a novel open field. We found that Df/+ mice showed
higher locomotor activity in the novel open field and that time
spent in the center zone of Df/+ mice was tended to be longer as
compared to that of WT mice; however, the differences did not
reach statistical significance (P= 0.055) (Fig. 2f, g). Finally, we
examined the effect of an atypical antipsychotic, risperidone, on
the greater startle response in Df/+ mice and found that the
intraperitoneal administration of risperidone effectively rescued
the greater startle response in Df/+ mice (Fig. 2h). Likewise, the
intraperitoneal administration of risperidone effectively rescued
impaired PPI at 68 and 71 dB (P= 0.048 and 0.035, respectively),
although the effect at 74 dB did not reach statistical significance
(P= 0.100) (Fig. 2i). Additionally, the percent of the PPI at 71 and
74 dB was significantly lower in saline-treated Df/+ mice as
compared to that in saline-treated WT mice (P= 0.031 and 0.027,
respectively), although the percent of the PPI at 68 dB was not
significantly different between saline-treated Df/+ and WT mice
(P= 0.120). The percent of the PPI at all dB levels was not
significantly different between risperidone-treated Df/+ and WT
mice (68 dB, P= 0.557; 71 dB, P= 0.326; 74 dB, P= 0.318).
Regarding apparent difference of statistical significance of the
PPI test between samples in Fig. 2b and saline-injected samples in
Fig. 2i, injection stress might be attributable to the difference,
although the precise reason for the discrepancy is currently
unknown.
Abnormally increased excitatory neural activity in the cerebral
cortex of Df/+ mice
Dysfunction of the cerebral cortex is critically involved in
impaired social interaction and PPI in mice [42, 43]. Using total
RNA obtained from the cerebral cortex of Df/+ mice and WT
littermates, we next conducted RNA sequence analysis to
explore the molecular mechanisms behind the behavioral
phenotypes. Interestingly, top-ranked differentially expressed
genes in the cortex between adult Df/+ mice and WT littermates
(|FC| > 2, P < 0.05), namely, Egr2, Fos, Cyr61, Nr4a1, Btg2, and
Dusp1 were immediate early genes, all of which showed
significantly increased expression in Df/+ mice (Fig. 3a). The
increased expression of these immediate early genes was
confirmed by RT-PCR analysis (Fig. 3b), further supporting
that the excitatory neural activity is abnormally increased in
Df/+ mice.
We further explored the whole-brain neuronal activity
patterns after specific behavioral tasks in Df/+ mice harboring
the Arc-dVenus reporter gene that expresses the destabilized
form of the fluorescent protein Venus (dVenus) driven by the
promoter of the immediate early gene Arc [39]. Given that Arc
was found exclusively in CaMKII-positive excitatory neurons in
the cerebral cortex [44], dVenus-positive cells are suggested to
be excitatory neurons. Using FAST, a high-speed serial-section-
ing imaging system that we recently developed [30, 31], we
unbiasedly examined dVenus expression in the whole brains of
adult Df/+ mice and WT littermates and found that the activity
of excitatory neurons in the auditory cortex was higher in Df/+
mice than in WT littermates after the social interaction (Fig. 4).
The excitatory neural activity was also slightly increased in the
retrosplenial cortex, anterior cingulate cortex, posterior parietal
cortex, orbitofrontal cortex, and somatosensory cortex; however,
this did not reach significant levels (Fig. 4). In other regions, such
as the infralimbic cortex, piriform cortex, visual cortex, ectorhinal
cortex, insular cortex, prelimbic cortex, entorhinal cortex, and
motor cortex, there were no significant differences in excitatory
neural activity between Df/+ mice and WT littermates (data not
shown).
Decreased PV-positive cells in the cerebral cortex in Df/+ mice
The increased excitatory neural activity in Df/+ mice may be
attributable to imbalanced excitatory and inhibitory neural
function. To examine this possibility, we focused on the expression
levels of excitatory and inhibitory neuronal marker genes and
determined that the expression level of Pvalb (encoding for PV) in
Df/+ mice was significantly lower than that in WT littermates
(Supplementary Table 1). The expression level of most of the
GABAergic neuronal marker genes, except for Slc6a13 (encoding
for GAT2), was virtually similar between Df/+ mice and WT
littermates (Supplementary Table 1). We also determined that the
expression level of most of the excitatory neuronal marker genes
was virtually similar between Df/+ mice and WT littermates
(Supplementary Table 2). Although the genotype-dependent
difference in the expression of Pvalb in the whole cortex was
not significant after Bonferroni’s correction for multiple testing,
these results suggest that the GABAergic system, but not the
excitatory system, is impaired in Df/+ mice. To examine the
decreased Pvalb expression in the specific brain regions, we then
performed immunohistochemical analysis for PV and determined
that the number of PV-positive cells was significantly decreased in
the sensory cortex of Df/+ mice compared to that of WT
littermates (Fig. 5a). We also performed immunohistochemical
analysis for SATB2, an excitatory neural marker, and determined
that the number of SATB2-positive cells was virtually similar in the
sensory cortex between Df/+ mice and WT littermates (Fig. 5b).
Taken together, the decreased number of PV neurons may be one
of the underlying mechanisms for impaired E/I balance and
hyperactivity in Df/+ mice.
DISCUSSION
Despite substantial efforts, the molecular and cellular etiology of
psychiatric disorders are largely unclear, partly because of the
limited good animal models of these diseases. In this study, we
generated an animal model of 3q29 deletion syndrome in which
the DNA region corresponding to human 3q29 CNV was deleted.
Important criteria for modeling diseases in animals are suggested
to be construct validity, predictive validity and face validity [6].
Since 3q29 deletion is strongly associated with increased risk for
schizophrenia as well as for intellectual disability and ASD [13–17],
the Df/+ mice generated in this study satisfies construct validity.
Furthermore, we determined that the mice displayed
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Fig. 2 Psychiatric disorder-related behavioral phenotypes in Df/+ mice. a Increased startle amplitude in Df/+ mice (WT, n= 10; Df/+, n= 10).
*P < 0.05, one-way analysis of variance (ANOVA). WT, wild-type littermates. b Impaired prepulse inhibition (PPI) in Df/+mice (WT, n= 10; Df/+,
n= 10). *P < 0.05, repeated two-way ANOVA with Bonferroni post hoc tests. c Impaired social interaction in Df/+ mice (WT, n= 10; Df/+, n=
10). *P < 0.05, one-way ANOVA. d Increased self-grooming activity (an index of repetitive behavior) in Df/+ mice (WT, n= 10; Df/+, n= 10).
*P < 0.05, one-way ANOVA. e Impaired fear conditioning in Df/+ mice (WT, n= 10; Df/+, n= 9). *P < 0.05, one-way ANOVA. f Increased open-
field activity in Df/+mice (WT, n= 8; Df/+, n= 9). *P < 0.05, one-way ANOVA. g Time in the center zone during the first 5 min in the open-field
test (WT, n= 8; Df/+, n= 9). h Rescue of the increased startle amplitude by risperidone administration in Df/+ mice (each n= 10). *P < 0.05,
**P < 0.01, two-way ANOVA with Bonferroni post hoc tests. i Rescue of the impaired PPI by risperidone administration in Df/+ mice (each n=
10). *P < 0.05, two-way ANOVA with Bonferroni post hoc tests. The percent of the PPI at all dB levels was not significantly different between
risperidone-treated Df/+ and WT mice (68 dB, P= 0.557; 71 dB, P= 0.326; 74 dB, P= 0.318). Data are presented as the mean ± s.e.m.
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abnormalities largely relevant to psychiatric disorders and that
these abnormalities were ameliorated by treatments that provide
therapeutic benefit in patients with schizophrenia and ASD. These
results suggest that, in addition to construct validity, Df/+ mice
achieve face validity and predictive validity. Importantly, in
addition to schizophrenia-related behavioral phenotypes, such
as impaired PPI, ASD-related behavioral phenotypes, such as social
dysfunction and increased repetitive self-grooming behavior, and
impaired fear learning, Df/+mice also showed growth defects and
microcephaly, which are reminiscent of the phenotypes in
patients with 3q29 deletion syndrome. Very recently, another
mouse model of 3q29 deletion syndrome has been published [18].
While the genetic backgrounds between the mice and our mice
are different (see below), several behavioral phenotypes, including
social interaction, cognitive function and acoustic startle, and
reduced body weight are reproducibly observed. In addition to
these, we newly identified the cellular phenotypes of neuronal
hyperactivation and the reduction of PV expression in the cortex
Fig. 3 Increased expression of immediate early genes in the cortex of Df/+ mice. a Top-ranked differentially expressed genes in the mouse
cortex between wild-type (WT) and Df/+ mice (RNA sequence, |FC| > 2, P < 0.05) (WT, n= 3; Df/+, n= 3). Note that the deleted genes in the
16B2, 3 region were not listed in the table (see Fig. 1e). b The expression of each immediately early gene was assayed by reverse transcription
PCR (RT-PCR) using total RNA from the cerebral cortex (WT, n= 4; Df/+, n= 5). *P < 0.05, **P < 0.01, Student’s t test. Data are presented as the
mean ± s.e.m.
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of Df/+ mice (Figs. 3–5). Overall, the 3q29 deletion mouse model
should be a key tool for unraveling the disease-causative
molecular mechanism underlying the phenotypes in 3q29
deletion syndrome and, especially, for studying the develop-
mental aspects of psychiatric disorders.
It has been shown that the genetic background of the mouse
model is suggested to modify the phenotypic expression of a
gene variant [6, 7, 45, 46]. Actually, while Df/+ mice (C57BL/6J
background) in this study showed impaired PPI, very recently
reported another mouse model of 3q29 deletion syndrome on
C57BL/6N background shows normal PPI [18]. The phenotypic
differences in the PPI test may be partly explained by the
differences in the genetic background. It will be important to
examine the phenotypes identified in this study on different
genetic backgrounds and under different environments.
The important findings in this study are that the excitatory
neural activity was abnormally increased in Df/+ mice (Figs. 3 and
4). Previous studies have suggested that an increased cellular E/I
balance is associated with circuit hyperexcitability and psychiatric
disorder-related behavioral phenotypes [28, 29, 47], although it
remains controversial whether it is a causative mechanism that
induced circuit hyperexcitability or a compensatory mechanism
[48]. It will be interesting to further analyze cellular and circuit
level electrophysiological properties in Df/+ mice so as to explore
the causative mechanisms of neuronal hyperexcitability observed
in Df/+ mice (Fig. 4). The limitation of this study is that, although
Fig. 4 Unbiased whole-brain activation mapping after social interaction. a Representative whole-brain imaging of Df/+ mice and wild-type
(WT) littermates carrying Arc-dVenus transgene subjected to the social interaction. Whole-brain images. Scale bar, 2 mm (left). Coronal images.
Scale bar, 1 mm (center). Magnifications of the areas outlined with white boxes in the coronal images. Scale bar, 200 μm (right). b dVenus-
positive cell counts (WT, n= 5; Df/+, n= 4). *P < 0.05, Student’s t test. Data are presented as the mean ± s.e.m.
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the impaired social interaction is an important phenotype of Df/+
mice in terms of a disease model, we examined excitatory neural
activity changes solely after the social interaction task. Future
unbiased whole-brain imaging combined with various behaviors is
important to comprehensively understand the etiology of 3q29
deletion syndrome at the brain network level.
We determined that the GABAergic system may be impaired
in Df/+ mice (Fig. 5, Supplementary Table 1). GABAergic
interneurons, which modulate neural circuit function through
inhibition of the activity of neighboring neurons, constitute a
diverse family, which are classified by their morphology,
electrophysiological properties, and specific molecular markers,
such as PV, somatostatin, cholecystokinin, neuropeptide Y,
calretinin, and calbindin [49–51]. Among them, PV-positive
interneurons play a key role in maintaining E/I balance and
ultimately cognitive functions [28, 29]. Interestingly, the expres-
sion level of PV mRNA is altered in patients with schizophrenia
and ASD [24, 26]. Consistent with this story, PV-knockout mice
exhibit imbalanced E/I and ASD-related behavioral abnormalities
[52, 53]. In Df/+ mice, the decreased PV-positive interneurons
may cause imbalanced E/I, resulting in abnormal behaviors
relevant to psychiatric disorders.
Approximately 22 and 24 genes are heterozygously deleted in
the human 3q29 deletion and Df/+ mice, respectively (Fig. 1a).
Among these gene products, Fbxo45, a ubiquitin ligase complex
protein, deletion may be one of key to the developmental
abnormalities because Fbxo45 is reported to be involved in
neuronal development, including interneuron development and
synaptic activity [54, 55]. In addition to Fbxo45, DLG1 (discs
large 1), and PAK2 (Cdc42/Rac-activating kinase 2) located in this
region are proposed to contribute to the phenotype of 3q29
deletion syndrome because these molecules seem to critically
regulate neural function [54–57]. Deletion of other gene
products, which are involved in neural development, may also
be associated with the molecular etiology of 3q29 deletion
syndrome. Specifically, since this study postulated that the
underlying mechanism for E/I imbalance may reside primarily in
PV neurons, precise gene expression analyses of 3q29 genes in
PV neurons would facilitate narrowing down of the disease-
causative gene(s) in 3q29 deletion syndrome. Further mechan-
istic studies in which each 3q29 gene is reintroduced into Df/+
mice will definitely determine which genes are causally related
to the disease phenotypes and, in the long run, may lead to the
identification of promising drug targets for 3q29 deletion
syndrome as well as schizophrenia and ASD.
An important unresolved issue is why the phenotypes of
patients with the same microdeletion are so diverse. Given that it
has been hypothesized that genetic background and modifiers
such as single-nucleotide polymorphisms affect the impact of the
microdeletion, comprehensive genetic analysis of patients with
3q29 microdeletion syndrome will surely be an important next
step to address the issue. Functional analysis of iPS cell-derived
neurons from multiple patients with 3q29 microdeletion syn-
drome, as well as CRISPR-mediated 3q29 deletion iPS cells, would
also be helpful.
Although, for generating Df/+ mice, we utilized the Cas9
nickase mutant (D10A) to greatly minimalize off-target mutagen-
esis [32, 33], it will be important to backcross Df/+ mice with
parental C57BL/6 mice to avoid possible off-target mutations
outside mouse chromosome 16.
In summary, our current findings suggest that Df/+ mice are
important tools not only to unravel the causal relationship
between the biological significance of genetic variants and
molecular etiology of the diseases but also to provide information
for the development of new effective treatment strategies for
schizophrenia and ASD.
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cortex in Df/+ mice. a PV immunostaining showing the decreased
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figures (left). Scale bar, 100 μm. Quantification of the number of PV-
positive cells (each n= 3) (right). *P < 0.05, Student’s t test. b SATB2
immunostaining showing the normal number of SATB2-positive
cells in adult Df/+ mice. Representative figures (left). Scale bar,
100 μm. Quantification of the number of SATB2-positive cells (each
n= 3) (right). Data are presented as the mean ± s.e.m.
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